[{"id":"971d9282-8be3-4d0b-a747-485b598d1a88","acronym":"","url":"https://clinicaltrials.gov/study/NCT03006302","created_at":"2024-01-03T19:17:30.474Z","updated_at":"2025-02-25T16:05:38.933Z","phase":"Phase 2","brief_title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","source_id_and_acronym":"NCT03006302","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" STAT6","pipe":"","alterations":" ","tags":["STAT6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • epacadostat (INCB024360) • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 08/05/2024","study_completion_date":" 08/05/2024","last_update_posted":"2024-10-08"},{"id":"fab7c1a5-865b-44d1-9464-2b668a7a8d95","acronym":"","url":"https://clinicaltrials.gov/study/NCT06626633","created_at":"2025-02-26T15:02:37.996Z","updated_at":"2025-02-26T15:02:37.996Z","phase":"Phase 1","brief_title":"2321GCCC: CRD3874-SI in Patients with Relapsed/refractory AML","source_id_and_acronym":"NCT06626633","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • STAT6 • IFI27 • IFNA1 • IL1B • NFKB2 • IRF7 • JUNB"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2024-10-04"}]